Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AltShock: Adrenaline in Cardiogenic Shock
NCT02591771Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Oct 2015
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epinephrine in cardiogenic shock, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Survival at 60 days. Started Oct 2015; status: completed.
02
Drugs
epinephrine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT02591771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591771.